Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Fallopian Tube Cancer Clinical Trials

A listing of Fallopian Tube Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (16) clinical trials

Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial Ovarian Fallopian Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

This trial is a Phase 1b/2a trial designed to evaluate the safety and efficacy of adding oral AL3818 to standard platinum-based chemotherapy such as carboplatin plus paclitaxel, concurrently and continued as a maintenance therapy for up to 12 months, in subjects with recurrent or metastatic endometrial, ovarian, fallopian, primary peritoneal, ...

Phase

Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer

The study is comprised of 2 phases: an open-label Safety Lead-in (Phase 1b) followed by an Expansion Phase (Phase 2). The Expansion Phase will evaluate the efficacy and safety of entinostat with avelumab when administered at the Recommended Phase 2 Dose (RP2D) versus avelumab alone in patients with advanced epithelial ...

Phase

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Study Groups: This study has 2 parts: a safety lead-in and Phase 2. If you are found to be eligible to take part in this study, you will be assigned to either the Safety Lead-in or the Phase 2 portion, depending on when you join the study. Up to 12 ...

Phase

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer

Ovarian cancer (OC) remains the most lethal gynecologic malignancy owing to late detection, intrinsic and acquired chemo-resistance and remarkable heterogeneity. There is an unmet medical need to develop new therapy modalities. In preclinical studies, GL-ONC1, has shown the ability to preferentially locate, colonize and destroy tumor cells in more than ...

Phase

Olaparib Durvalumab and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

PRIMARY OBJECTIVES: I. To assess the safety and toxicity of the combination of PARP inhibitor olaparib with anti-PD-L1 antibody durvalumab and anti-CTLA4 antibody tremelimumab. (Phase I) II. To assess the impact of the combination of olaparib with durvalumab and tremelimumab on progression free survival (PFS) rates. (Phase II) SECONDARY OBJECTIVES: ...

Phase

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose of the combination of veliparib (ABT-888) and weekly topotecan (topotecan hydrochloride) in adult patients with advanced solid tumors. (Phase I) II. To identify any anti-tumor activity of this treatment combination, as assessed by objective response in patients with advanced solid tumors. ...

Phase

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cavity Cancer

OBJECTIVES: Primary - Determine the safety and tolerability of combination therapy comprising phenoxodiol and docetaxel in patients with recurrent or persistent advanced ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. Secondary - Determine the effect of phenoxodiol on the toxicity of docetaxel using a weekly treatment regimen. - Determine ...

Phase

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

Long-term survival in stage IV serous ovarian, peritoneal, and fallopian tube cancer is poor and has not significantly improved over the last decades. Standard treatment consists of debulking surgery and six courses of carboplatin and paclitaxel. Nevertheless, the disease recurs in >90% of women, usually within two years. Since early ...

Phase

Atezolizumab Guadecitabine and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. To determine the safety of fixed doses of atezolizumab (MPDL3280A) in combination with guadecitabine (SGI-110). (Phase I) II. To evaluate toxicity of the combination as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. (Phase I) III. To study if SGI-110 ...

Phase

DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Poly ICLC and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian Fallopian Tube or Primary Peritoneal Cancer in Remission

PRIMARY OBJECTIVES: I. To determine the safety of fixed doses of DEC205mAb-NY-ESO-1 fusion protein (DEC-205/NY-ESO-1 fusion protein CDX-1401) with adjuvant poly-ICLC given as a vaccine in combination with INCB024360 (IDO1 inhibitor INCB024360). (Phase I) II. To evaluate toxicity as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse ...

Phase